ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

  • End date
    Jul 26, 2023
  • participants needed
  • sponsor
    M.D. Anderson Cancer Center
Updated on 19 June 2022
platelet count
serum pregnancy test
measurable disease
breast cancer
direct bilirubin
growth factor
investigational drug
gilbert's syndrome
international normalized ratio
neutrophil count
liver metastasis
tumor cells
blood transfusion
human epidermal growth factor
solid tumors
solid tumour
epidermal growth factor
somatic mutation
mdm2/mdmx inhibitor alrn-6924
tp53 gene
recurrent breast cancer


This phase Ib trial studies the side effects and best dose of ALRN-6924 when given together with paclitaxel in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as ALRN-6924 and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.



I. Determine the dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD) of MDM2/MDMX inhibitor ALRN-6924 (ALRN-6924) in combination with paclitaxel in adult patients with advanced or metastatic solid tumors with wild-type (WT) TP53.

II. Evaluate the safety and tolerability of ALRN-6924 in combination with paclitaxel in patients with advanced or metastatic WT TP53 solid tumors.


I. Evaluate the anti-tumor activity of ALRN-6924 in combination with paclitaxel in solid tumors (in dose escalation) and hormone-receptor positive breast cancer (in expansion).

II. Describe the pharmacokinetics (PK) of ALRN-6924 and paclitaxel in plasma following single and multiple intravenous (IV) infusions (cycle 1 day 1, day [D]2, D15 and cycle 2 D1).


I. Assess predictive and pharmacodynamic (PD) markers of response. II. Assess the effects of ALRN-6924 and paclitaxel on cell proliferation and apoptosis.

III. Assess the effects of ALRN-6924 and paclitaxel on cell-free deoxyribonucleic acid (DNA) (cfDNA) dynamics and macrophage inhibitory cytokine-1 (MIC-1).

OUTLINE: This is a dose-escalation study of MDM2/MDMX inhibitor ALRN-6924.

Patients receive paclitaxel intravenously (IV) over 1 hour and MDM2/MDMX inhibitor ALRN-6924 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 2 months for 1 year and then every 3 months thereafter.

Condition Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm
Treatment Paclitaxel, MDM2/MDMX Inhibitor ALRN-6924
Clinical Study IdentifierNCT03725436
SponsorM.D. Anderson Cancer Center
Last Modified on19 June 2022


Yes No Not Sure

Inclusion Criteria

years of age or older
Histologically- or cytologically-confirmed solid tumors (excluding lymphomas) that are metastatic or unresectable and that meet the following criteria: a) Escalation and expansion cohorts: wild type (WT) TP53 status defined as no mutation on a Clinical Laboratory Improvement Amendments (CLIA)-certified next-generation sequencing (NGS) assay that has sequenced the full length TP53 gene. Patients can be enrolled based on tissue testing or liquid biopsies. If enrolled based on liquid biopsies, testing should have detected other somatic mutations; b) Expansion cohort only: estrogen receptor (ER) positive (> 1%), human epidermal growth factor 2 (HER2) negative, WT TP53 metastatic or inoperable locally advanced or locally recurrent breast cancer. Patients can be HER2 0+ or 1+, 2+ or FISH non-amplified to be considered HER2 negative
Standard treatment with therapies known to confer a survival benefit does not exist, is no longer effective or tolerated, or the patient declines standard treatment
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. In the dose escalation stage, patients without measurable disease by RECIST 1.1, but evaluable disease are also eligible
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Serum creatinine =< 1.5 x upper limit of normal (ULN) or >= 45 mL/min/1.73 m^2 by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation for subjects with creatinine levels > 1.5 x institutional ULN
Total bilirubin =< 1.5 x ULN, or direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 x ULN, or unless due to Gilbert's Syndrome
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN if hepatic abnormalities are related to underlying liver metastases or liver/biliary primary
Absolute neutrophil count (ANC) >=1500/mm^3 (without granulocyte-colony stimulating factor [GCSF] in the 2 weeks prior to treatment start)
Platelet count >= 100,000/mm^3
Hemoglobin >= 9 g/dL (without blood transfusion in the 2 weeks prior to treatment start)
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN
All patients (males and females) of childbearing potential must agree to use medically effective contraception during the study and for 6 months after the last dose of study drugs. Females must have a negative serum pregnancy test during screening and a negative urine pregnancy test at study day 1 prior to initiation of treatment
Have no concomitant medical condition that in the judgment of the investigator will interfere with the patient's ability to participate in the study or render such participation medically inappropriate
No medical history of another cancer (except basal or squamous cell skin cancer or in situ cervical cancer, or carcinomas in situ or other malignancies with a >= 95% 5-year survival) within 2 years of the start of study treatment
No investigational drug or other anticancer treatments (including chemotherapy or radiation therapy) within 21 days or at least 5 half-lives, whichever is shorter, of the start of the study treatment
No major surgery within 1 month of treatment and fully recovered
Willing and able to provide informed consent

Exclusion Criteria

Previous treatment with investigational agents that inhibit MDM2 or MDMX activity
Known active hepatitis B, hepatitis C and/or human immunodeficiency virus (HIV)-positive patients who have a cluster of differentiation 4 (CD4) count < 200\. No antiretroviral medications that are CYP3A4 substrates will be allowed
Requirement for therapeutic anticoagulation
Pre-existing history of or known cardiovascular risk: a) History of acute coronary syndromes within 6 months prior to the first dose of ALRN-6924 (including myocardial infarction, unstable angina, coronary artery bypass graft, angioplasty, or stenting); b) Uncontrolled hypertension; c) Pre-existing cardiac failure (New York Heart Association class III-IV); d) Atrial fibrillation on anti-coagulants; e) Clinically significant uncontrolled arrhythmias; f) Corrected QTcF interval on screening electrocardiography (ECG) >= 450 msec for males and >= 470 msec for females (QTcF > 480 msec for any patient with a bundle branch block)
Clinically significant gastrointestinal bleeding within 6 months prior to the start of study treatment
Females who are pregnant or nursing
Symptomatic central nervous system (CNS) metastases by history, clinical signs or radiologic findings. Stable brain metastases (1 month after completion of treatment) confirmed by imaging are allowed
Known hypersensitivity to any study drug component
The required use of any concomitant medications that are predominantly cleared by hepatobiliary transporters, Organic-anion-transporting polypeptide (OATP) members OATP1B1 and OATP1B3, on the day of the ALRN-6924 infusion or within 48 hours after an ALRN-6924 infusion
Patients with grade >= 2 neuropathy will be excluded
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note